A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Daridorexant 10 mg; Drug: Daridorexant 25 mg

• Registration Number: NCT05877222
• Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Brief Summary

A Phase 1 trial to investigate bioequivalence between 5 × 10 mg tablets and 2 × 25 mg tablets of daridorexant in healthy male and female Japanese participants

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-17
• Study First Submitted QC: 2023-05-17
• Study First Posted: 2023-05-26
• Study Start: 2023-06-23
• Status Verified: 2023-08
• Primary Completion: 2023-08-04
• Study Completion: 2023-08-04
• Last Update Submitted: 2023-08-15
• Last Update Posted: 2023-08-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Signed informed consent in a language understandable to the participant prior to any trial-mandated procedure.
• Healthy male and female participants aged between 18 and 65 years (inclusive) at Screening.
• Body mass index of 18.5 to 29.9 kg/m2 (inclusive) at Screening.
• Participant must be of native Japanese descent (all parents/grandparents of Japanese descent).
• Participant must not have been away from Japan for more than 10 years (at Screening visit).
• Participant's lifestyle should not have changed significantly since relocation from Japan.

Exclusion Criteria

• Known hypersensitivity to daridorexant, or any of its excipients.
• History of narcolepsy or cataplexy.
• Clinically relevant findings on the physical examination at Screening.
• Clinically relevant findings on 12-lead ECG, recorded after 5 min in a supine position at Screening.
• Clinically relevant findings in clinical laboratory tests (hematology and clinical chemistry) at Screening.
• Clinically relevant findings in systolic blood pressure, diastolic blood pressure, and pulse rate, measured on either arm, after 5 min in the supine position at Screening.
• History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed if performed > 12 weeks prior to administration of first study treatment, cholecystectomy not allowed).
• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Treatment A (5 × 10 mg daridorexant)	Daridorexant 10 mg	Participants will receive a single oral dose of 5 × 10 mg daridorexant.
Treatment B (5 × 25 mg daridorexant)	Daridorexant 25 mg	Participants will receive a single oral dose of 2 × 25 mg daridorexant.

Primary Outcome Measures

Name	Time	Method
Cmax	Blood samples for PK analysis will be taken at several timepoints from treatment administration on Day 1 to Day 3 of Study periods 1 and 2 (Total duration: up to 4 days)
AUC0-t	Blood samples for PK analysis will be taken at several timepoints from treatment administration on Day 1 to Day 3 of Study periods 1 and 2 (Total duration: up to 4 days)

Trial Locations

Locations (1)

Anaheim Clinical Trials; 🇺🇸 Anaheim, California, United States